Provided by Tiger Trade Technology Pte. Ltd.

Cidara Therapeutics

221.38
0.0000
Volume:- -
Turnover:- -
Market Cap:6.96B
PE:-19.73
High:221.38
Open:221.38
Low:221.38
Close:221.38
52wk High:221.42
52wk Low:15.22
Shares:31.44M
Float Shares:24.87M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-11.2200
EPS(LYR):-26.7460
ROE:-68.70%
ROA:-29.35%
PB:16.48
PE(LYR):-8.28

Loading ...

Merck close to deal to acquire Cidara Therapeutics, FT reports

TIPRANKS
·
Nov 14, 2025

Stock Track | Cidara Therapeutics Soars 13.63% After-Hours on Potential Merck Acquisition

Stock Track
·
Nov 14, 2025

Stock Track | Cidara Therapeutics Soars 13.63% After-Hours on Potential Merck Acquisition

Stock Track
·
Nov 14, 2025

BRIEF-Merck Nearing Deal For Flu Treatment Start-Up Cidara - FT

Reuters
·
Nov 14, 2025

a Deal Valuing Cidara at a Premium to Its $3.3Bn Market Capitalisation Could Be Announced as Soon as Friday - FT

THOMSON REUTERS
·
Nov 14, 2025

Merck Nearing Deal for Flu Treatment Start-up Cidara - FT

THOMSON REUTERS
·
Nov 14, 2025

Cidara Therapeutics price target raised to $145 from $137 at RBC Capital

TIPRANKS
·
Nov 08, 2025

Stock Track | Cidara Therapeutics Soars 5.87% on Analyst Upgrades and Positive Outlook

Stock Track
·
Nov 07, 2025

RBC Capital Adjusts Price Target on Cidara Therapeutics to $145 From $137, Maintains Outperform Rating

MT Newswires Live
·
Nov 07, 2025

H.C. Wainwright Sticks to Its Buy Rating for Cidara Therapeutics (CDTX)

TIPRANKS
·
Nov 07, 2025

Cidara Therapeutics Is Maintained at Buy by Needham

Dow Jones
·
Nov 07, 2025

Positive Outlook on Cidara Therapeutics: Progress in CD388 Flu Program and Strategic Trial Advancements

TIPRANKS
·
Nov 07, 2025

UPDATE: Cidara Therapeutics Q3 Adj. EPS $(1.43) Misses $(1.35) Estimate

Benzinga
·
Nov 07, 2025

Cidara Therapeutics reports Q3 EPS ($3.10), consensus ($1.33)

TIPRANKS
·
Nov 07, 2025

Cidara Therapeutics Q3 Operating Expenses USD 88.628 Million

Reuters
·
Nov 07, 2025

Cidara Therapeutics Q3 EPS $(3.10) Misses $(1.33) Estimate

Benzinga
·
Nov 07, 2025

Cidara Therapeutics reports Q3 net loss of $83.2 million and cash holdings of $476.5 million

Reuters
·
Nov 07, 2025

Cidara Therapeutics to Participate in November Investor Conferences

GlobeNewswire
·
Oct 28, 2025

Cidara Therapeutics’ CD388 Study: A Potential Game-Changer in Influenza Prevention

TIPRANKS
·
Oct 28, 2025

H.C. Wainwright reiterates Cidara as top pick after influenza data

TIPRANKS
·
Oct 24, 2025